Outcomes With Finerenone by Baseline Treatment Goals in Type 2 Diabetes and Chronic Kidney Disease: A FIDELITY Analysis.

Saved in:
Bibliographic Details
Title: Outcomes With Finerenone by Baseline Treatment Goals in Type 2 Diabetes and Chronic Kidney Disease: A FIDELITY Analysis.
Authors: Neves JS; RISE-Health, Department of Surgery and Physiology, Faculty of Medicine of the University of Porto, Porto, Portugal.; Department of Endocrinology, Diabetes and Metabolism, ULS São João, Porto, Portugal., Leite AR; RISE-Health, Department of Surgery and Physiology, Faculty of Medicine of the University of Porto, Porto, Portugal.; Department of Endocrinology, Diabetes and Metabolism, ULS São João, Porto, Portugal., Vasques-Nóvoa F; RISE-Health, Department of Surgery and Physiology, Faculty of Medicine of the University of Porto, Porto, Portugal., Pitt B; Department of Medicine, University of Michigan School of Medicine, Ann Arbor, Michigan, USA., Filippatos G; Department of Cardiology, Attikon University Hospital, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece., Ruilope LM; Cardiorenal Translational Laboratory and Hypertension Unit, Institute of Research imas12, Madrid, Spain.; CIBER-CV, Hospital Universitario 12 de Octubre, Madrid, Spain.; Faculty of Sport Sciences, European University of Madrid, Madrid, Spain., Rossing P; Steno Diabetes Center Copenhagen, Copenhagen, Denmark.; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark., Anker SD; Department of Cardiology (CVK) of German Heart Center Charité, German Centre for Cardiovascular Research (DZHK) Partner Site Berlin, Charité Universitätsmedizin, Berlin, Germany., Savarese G; Department of Clinical Science and Education, Södersjukhuset, Karolinska Institutet, Stockholm, Sweden., Scott CAB; Clinical Statistics and Analytics, Bayer Corporation, Whippany, New Jersey, USA., Lage A; Cardiology and Nephrology Clinical Development, Bayer SA, São Paulo, Brazil., Brinker MD; Cardiology and Nephrology Clinical Development, Bayer AG, Leverkusen, Germany., Ferreira JP; RISE-Health, Department of Surgery and Physiology, Faculty of Medicine of the University of Porto, Porto, Portugal.; Université de Lorraine, Inserm, Centre d'Investigations Cliniques-Plurithématique 14-33, Inserm U1116, CHRU Nancy, F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France.
Source: Diabetes, obesity & metabolism [Diabetes Obes Metab] 2026 Jul; Vol. 28 (7), pp. 6022-6033. Date of Electronic Publication: 2026 Apr 24.
Publication Type: Journal Article; Randomized Controlled Trial; Multicenter Study; Clinical Trial, Phase III
Journal Info: Publisher: Wiley-Blackwell Country of Publication: England NLM ID: 100883645 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1463-1326 (Electronic) Linking ISSN: 14628902 NLM ISO Abbreviation: Diabetes Obes Metab Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1463-1326
DOI:10.1111/dom.70750